U.S. FDA approves GlaxoSmithKline’s HIV drug Tivicay

A no entry sign is pictured outside the GlaxoSmithKline building in Hounslow, west London June 18, 2013.WASHINGTON (Reuters) – The U.S. Food and Drug Administration said on Monday it has approved GlaxoSmithKline Plc's drug Tivicay to treat the most common strain of HIV, the virus that causes AIDS. The once-daily drug, known generically as dolutegravir, belongs to a novel class known as integrase inhibitors that block the virus from entering cells. Tivicay is owned by ViiV Healthcare, an HIV joint venture between GSK, Pfizer Inc and Shionogi & Co Ltd in which GSK is the largest shareholder, with a 76.5 percent stake. …



Sexual Health News Headlines – Yahoo! News